LFB - BIOTECHNOLOGIES Patent applications |
Patent application number | Title | Published |
20140093491 | RECOMBINANT OR TRANSGENIC FACTOR VII COMPOSITION, EACH FACTOR VII MOLECULE HAVING TWO N-GLYCOSYLATION SITES WITH DEFINED GLYCAN UNITS - The invention is related to a composition of recombinant or transgenic Factor VII, each molecule of Factor VII of the composition exhibiting two N-glycosylation sites, wherein, among all the molecules of FVII of the composition, the rate of Galα1,3G al glycan moieties is comprised between 0 and 4%. The invention is also related to a process for preparing such a composition of FVII. | 04-03-2014 |
20140050722 | CHIMERIC ANTI-RICIN ANTIBODY - A chimeric monoclonal antibody targeted to ricin is presented. The light chain and heavy chain constant regions are respectively made up of the light chain and heavy chain constant regions of human immunoglobulin, and the light chain and heavy chain variable regions respectively include the light chain and heavy chain variable regions of macaque immunoglobulin. The antibody does not substantially induce any immune response against chimeric antibodies. | 02-20-2014 |
20130344567 | METHOD FOR IMMOBILISING NUCLEIC LIGANDS - The invention relates to a method for immobilizing nucleic ligands including at least one reactive amine function, by grafting on an activated solid substrate, including a step of coupling said nucleic acids on said activated solid substrate having a pH of less than 6. | 12-26-2013 |
20130315820 | USE OF AN ANTIBODY DIRECTED AGAINST A MEMBRANE PROTEIN - An antibody directed against the BDCA-2 protein for the prevention or the treatment of the pathologies involving activation of the plasmacytoid dendritic cells. | 11-28-2013 |
20130295646 | METHOD FOR EXTRACTING A PROTEIN FROM MILK - The invention relates to a method for extracting a protein from milk, having at least one hydrophobic pocket and a negative charge to the natural pH of milk, that comprises the following steps: a) skimming and delipidation of the milk; b) passing the delipidated and skimmed fraction containing the protein on a chromatographic substrate on which is grafted a ligand having both a hydrophobic characteristic and an ionic characteristic in pH conditions enabling the protein to be retained on the substrate, the pH being higher than 4.6; c) elution of the protein; d) purification of the eluted fraction by removing the milk proteins from the eluted fraction; and e) recovering the protein. | 11-07-2013 |
20130216476 | USE OF AN ANTI-CD71 ANTIBODY FOR PREPARING A MEDICAMENT - The use of an anti-CD71 monoclonal antibody or a fragment of an abovementioned antibody capable of binding to the CD71 antigen for the preparation of a drug intended for the prevention or treatment of myelomas. | 08-22-2013 |
20130189244 | RECOMBINANT OR TRANSGENIC FACTOR VII COMPOUND HAVING A MAJORITY OF GLYCAN, BIANTENNARY, BISIALYLATED AND NON-FUCOSYLATED FORMS - The present invention concerns a recombinant or transgenic factor VII compound, each factor VII molecule of the compound having glycan forms linked to N-glycosylation sites, wherein among all the factor VII molecules in said compound, glycan, biantennary, bisialylated and non-fucosylated forms are in the majority. The invention also concerns such a compound for use as a medication, and a method for preparing said compound, among others. | 07-25-2013 |
20130143302 | METHOD FOR PURIFYING GLA-DOMAIN COAGULATION PROTEINS - A method for purifying GLA-domain coagulation proteins, includes the following steps: a) bringing a sample containing one or more GLA-domain coagulation proteins into contact with an affinity substrate on which nucleic aptamers which bind specifically to the GLA-domain coagulation proteins are immobilized, in order to form complexes between (i) the nucleic aptamers and (ii) the GLA-domain coagulation protein(s), b) releasing the GLA-domain coagulation protein(s) from the complexes formed in step a), and c) recovering the GLA-domain coagulation protein(s) in a purified form. | 06-06-2013 |
20130136743 | NOVEL MUTATED HUMANIZED 12G4 ANTIBODIES AND THE FRAGMENTS THEREOF AGAINST THE HUMAN ANTI-MULLERIAN HORMONE RECEPTOR TYPE II - Novel mutated humanized 12G4 antibodies, and fragments thereof, directed against the anti-Müllerian hormone type II receptor. | 05-30-2013 |
20130122546 | NOVEL SIGNAL PEPTIDE, AND USE THEREOF FOR PRODUCING RECOMBINANT PROTEINS - A use of a signal peptide for producing a recombinant polypeptide of interest in an expression system, the signal peptide includes at least 12 amino acids of formula (I): | 05-16-2013 |
20120271039 | METHOD FOR PURIFYING ACTIVE GLA-DOMAIN COAGULATION PROTEINS - A method for purifying biologically active GLA-domain coagulation proteins, includes the following steps: a) bringing a sample that contains one or more GLA-domain coagulation proteins and may contain biologically inactive molecules of GLA-domain protein(s), into contact with an affinity substrate on which nucleic aptamers that bind specifically to at least one biologically active GLA-domain coagulation protein are immobilized, in order to form complexes between (i) the nucleic aptamers and (ii) the GLA-domain coagulation protein(s), b) releasing the GLA-domain coagulation protein(s) from the complexes formed in step a), and c) recovering the biologically active GLA-domain coagulation protein(s) in a purified form. | 10-25-2012 |
20120258100 | CHIMERIC ANTI-RICIN ANTIBODY - A chimeric monoclonal antibody targeted at ricin, in which the light chain and heavy chain are such that:
| 10-11-2012 |
20120122179 | MEANS FOR PURIFYING A PROTEIN OF BLOOD PLASMA AND METHODS FOR IMPLEMENTING SAME - An affinity substrate for the selective binding of a protein of blood plasma includes a solid substrate material on which are immobilized deoxyribonucleic aptamers specifically binding with the plasma protein. | 05-17-2012 |
20120100133 | USE OF ANTI-CD20 ANTIBODY FOR TREATING PRIMARY INTRAOCULAR LYMPHOMA - An embodiment relates to a monoclonal antibody directed against the CD20 antgen, in which the variable region of each of the light chains is coded by murine nucleic acid sequence SEQ ID NO:1, the variable region of each of the heavy chains is coded by murine nucleic acid sequence SEQ ID NO: 2, and the constant regions of the light chains and of the heavy chains originate from a non-murine species, said antibody being used for treating primary intraocular lymphoma. | 04-26-2012 |
20120087908 | FACTOR VII COMPOSITION - The invention relates to a stable pharmaceutical composition in liquid form or in solid form, comprising factor VII, said composition being free of mannitol and of sucrose, or even also of any antioxidant. | 04-12-2012 |
20120041056 | NUCLEIC ACIDS SPECIFICALLY BINDING WITH HUMAN FACTOR VII/VIIA AND USES THEREOF - A nucleic acid includes at least 15 nucleotides with a length specifically binding with the human factor VII/VIIa. | 02-16-2012 |
20120040905 | MEANS FOR PURIFYING A COAGULATION PROTEIN, AND METHODS FOR IMPLEMENTING SAME - An affinity substrate for selectively binding a coagulation protein, includes a substrate solid on which nucleic aptamers binding specifically to the coagulation protein are immobilized. | 02-16-2012 |
20120009188 | OPTIMIZED FC VARIANTS - A variant of a parent polypeptide including an Fc region, which variant exhibits increased binding to FcRn as compared to the parent polypeptide and includes at least one amino acid modification in the Fc region. | 01-12-2012 |
20110311556 | ANTI-RHESUS D MONOCLONAL ANTIBODY - The invention relates to an anti-RhD monoclonal antibody, which is a tetrameric IgG1 immunoglobulin composed of two heavy chains and two light chains, the heavy chain comprising the amino acid sequence SEQ ID No. 2, harboring a phenylalanine residue at position 68, and the light chain comprising the amino acid sequence SEQ ID No. 4. | 12-22-2011 |
20110274684 | CYTOTOXIC ANTIBODIES DIRECTED AGAINST ANTIBODIES INHIBITING FACTOR VIII - The invention relates to an anti-idiotypical antibody targeting an antibody inhibiting the human fact VIII, said inhibiting antibody targeting the C2 region of the human factor VIII, the variable region of each of the light chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 1, and the variable region of each of the heavy chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 2, the constant regions of the light chains and the heavy chains being constant regions from a non-murine species. The invention also relates to the use of said antibody for activating the FcγRIII receptors of cytotoxic immune cells, and to the production of a medicament especially for the treatment of haemophilia A. | 11-10-2011 |
20110250702 | ISOLATED PEPTIDES OF RABBIT FACTOR VII - The present disclosure relates to peptides isolated from rabbit factor VII and to the use of thereof for the generation of antibodies specifically directed against the latter. The disclosure also relates to the use of antibodies directed against rabbit factor VII for the detection or purification of rabbit factor VII, specifically when said rabbit factor VII is in a biological sample which also contains human factor VII. | 10-13-2011 |
20110201033 | G IMMUNOGLOBULIN USED AGAINST ANTHRAX TOXINS - An immunoglobulin of the G class (IgG) directed against the protective antigen (PA) of the anthrax toxin, includes:
| 08-18-2011 |
20110165613 | STABLE CLONE CELL EXPRESSING A PRION - The invention relates to a cell clone derived from the MovS6 line, said cell clone expressing a prion protein PrP and being capable of tolerating the replication or propagation of the pathological form PrPsc of said PrP, characterized in that its titre with respect to marker for infection with a non-conventional transmissible agent (NCTA) is stable at least up to the 6 | 07-07-2011 |
20110162094 | MODIFIED HUMAN FACTOR VII/VIIA AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME - Modified factors VII/VIIa with a high stability, nucleic acids encoding such modified factors VII/VIIa, and methods of preparing the same. | 06-30-2011 |
20110151476 | METHOD OF DETECTION AND/OR TITRATION IN VITRO OF AN UNCONVENTIONAL TRANSMISSIBLE AGENT - The invention relates to an in vitro method for the in vitro detection and/or titration of a non-conventional transmissible agent (NCTA) or of a protein of pathological conformation, which is a marker for infectiousness related to the NCTA, in a sample, comprising: replication or propagation, in cells in culture, of the NCTA present in the sample, and then repeated incubation with a substrate which allows amplification of the NCTA or of the protein of pathological conformation, nonpathological conformer of the NCTA, before determination of the presence and/or of the amount of the NCTA or of the protein of pathological conformation in the sample. | 06-23-2011 |
20110097754 | METHOD FOR MEASURING ACTIVATED FACTOR VII LEVEL IN A SAMPLE - The present disclosure relates to a method for measuring the activated factor VII level in a sample to be tested, including the steps of: a) mixing the test sample with a plasma free of factor VII (FVII) and free of at least another factor selected from among factor VIII (FVIII), factor IX (FIX), and factor XI (FXI), the test sample+plasma having a final FVII+FVIIa concentration of 10 pM to 80 pM; b) adding initiating components from the thrombin generation reaction; c) obtaining a thrombogram when carrying out a thrombin generation test (TGT) on the mixture from step b); d) comparing at least one of the thrombogram parameters from step c) with a homologous parameter obtained from standard thrombograms established on the basis of standard samples, the activated factor VII level of which is known and varies with each standard sample; e) deducing, from step d), an activated factor VII level measurement in the test sample. | 04-28-2011 |
20110097715 | METHOD FOR PURIFYING OR DETECTING A TARGET PROTEIN - A method for purifying or detecting a target protein present in a solution, includes, before carrying out the actual detection or purification step, a step of contacting the solution with an aptamer binding specifically to the target protein, where the aptamer does not bind to a protein homologous to the target protein that could also be present in the solution. | 04-28-2011 |
20100305305 | METHOD FOR PURIFYING FACTOR VIII AND VON WILLEBRAND FACTOR - The purification method includes, starting from a solution selected from (i) a solution containing a mixture of FVIII and FvW, (ii) a solution containing FvW, (iii) a solution derived from a secretion of a non-human animal and (iv) a solution derived from a FVIII-containing plant extract, a step of absorption of FVIII or FvW on an ion-exchange chromatography filter-type membrane. | 12-02-2010 |
20100197578 | DEMANNOSYLATED RECOMBINANT FACTOR VIII [[VII]] FOR THE TREATMENT OF PATIENTS WITH HAEMOPHILIA A - There is provided in accordance with the practice of this invention a demannosylated Factor VIII, the immunogenicity of which is substantially decreased or abolished in Human. The modified factor VIII is disclosed together with the modified amino acid sequence, changed by at least one substitution. The modified factor VIII is useful for hemophiliacs, either to avoid or prevent the action of inhibitory anti-FVIII antibodies. | 08-05-2010 |
20100193440 | USE OF A CHROMATOGRAPHY SUBSTRATE FOR REDUCING THE AMOUNT OF ADAMTS13 IN A SOLUTION DERIVED FROM PLASMA - An ion-exchange chromatography support for reducing the ADAMTS13 amount present in a plasma-derived solution containing human von Willebrand factor. The support includes a large-pore, vinyl polymer-type resin bearing DEAE groups, and a buffer including trisodium citrate, sodium chloride, calcium chloride, glycine and lysine. | 08-05-2010 |
20100143370 | SET OF MEANS FOR TREATING A MALIGNANT PATHOLOGY, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE - Kit of parts for treating a malignant pathology, an auto-immune disease or an infectious disease, comprising an effector cell which expresses the FcγRIII receptor (CD16) on its surface, and a monoclonal antibody, the affinity of the Fc region of said monoclonal antibody for CD16 being greater than the affinity of the Fc region of the polyclonal immunoglobulins for CD16. | 06-10-2010 |
20100098706 | MONOCLONAL ANTIBODY DIRECTED AGAINST THE HUMAN LDL RECEPTOR - The invention relates to a monoclonal antibody directed against the human LDL (Low Density Lipoprotein) receptor, in which the variable region of each of the light chains is coded by the murine nucleic acid sequence SEQ ID NO: 5, the variable region of each of the heavy chains is coded by the murine nucleic acid sequence SEQ ID NO: 7, or by nucleic acid sequences having a sufficient homology with the sequences SEQ ID NO: 5 and SEQ ID NO: 7 so that the nature and the affinity of the bond between the antibody and its antigene are not modified, while the constant regions of the light chains and the heavy chains thereof are constant regions from a non-murine species. | 04-22-2010 |
20100047428 | METHOD FOR THE EXTRACTION OF ONE OR SEVERAL PROTEINS IN MILK - The invention is related to a process for extracting at least one protein present in milk, said protein exhibiting an affinity for the complexed or non-complexed calcium ions of said milk, comprising the following steps consisting of:
| 02-25-2010 |
20090317373 | Inhibition of the Anti-FVIII Immune Response - The invention relates to a compound capable of inhibiting the endocytosis of FVIII (factor VIII) by immune system cells capable of endocytosing the antigen and to the therapeutic use of such a compound for the manufacture of a medicament for use in the treatment of hemophiliacs in order to reduce the immunogenicity of FVIII and/or increase the half-life of FVIII. | 12-24-2009 |
20090311239 | RECOMBINANT OR TRANSGENIC FACTOR VII COMPOSITION, EACH FACTOR VII MOLECULE HAVING TWO N-GLYCOSYLATION SITES WITH DEFINED GLYCAN UNITS - The invention is related to a composition of recombinant or transgenic Factor VII, each molecule of Factor VII of the composition exhibiting two N-glycosylation sites, wherein, among all the molecules of FVII of the composition, the rate of Galα1,3Gal glycan moieties is comprised between 0 and 4%. The invention is also related to a process for preparing such a composition of FVII | 12-17-2009 |
20090239788 | RECOMBINANT OR TRANSGENIC FACTOR VII COMPOUND HAVING A MAJORITY OF GLYCAN, BIANTENNARY, BISIALYLATED AND NON-FUCOSYLATED FORMS - The present invention concerns a recombinant or transgenic factor VII compound, each factor VII molecule of the compound having glycan forms linked to N-glycosylation sites, wherein among all the factor VII molecules in said compound, glycan, biantennary, bisialylated and non-fucosylated forms are in the majority. The invention also concerns such a compound for use as a medication, and a method for preparing said compound, among others. | 09-24-2009 |
20090176220 | ANTIBODY CHARACTERIZATION TEST - The present invention relates to a method for measuring the ability of an antibody preparation to activate an Fc receptor, wherein this method comprises the following steps: a) aggregating said antibodies with one another, b) bringing cells expressing an Fc receptor into contact with said aggregated antibodies, and c) measuring the reaction of the cells resulting from the activation of the Fc receptor of said cells by the Fc region of said antibodies. | 07-09-2009 |
20090175789 | Antibody raised against the ldl receptor - The present invention relates to a monoclonal antibody raised against the human LDL (Low Density Lipoprotein) receptor, binding to the peptide corresponding to amino acids 195-222 (SEQ ID NO: 1) in the peptide sequence for the human LDL receptor; to the use thereof as a drug; to a pharmaceutical composition containing this antibody; and to the use thereof in immunohistochemical analyses of cancerous, healthy, or cirrhotic tissues, in Western-Blot or ELISA analyses, or in in vivo quantification tests. | 07-09-2009 |
20090130094 | Cytotoxic Antibodies Directed Against Antibodies Inhibiting Factor VIII - The invention relates to an anti-idiotypical antibody targeting an antibody inhibiting the human factor VIII, said inhibiting antibody targeting the C2 region of the human factor VIII, the variable region of each of the light chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 1, and the variable region of each of the heavy chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 2, the constant regions of the light chains and the heavy chains being constant regions from a non-murine species. The invention also relates to the use of said antibody for activating the FcγRIII receptors of cytotoxic immune cells, and to the production of a medicament especially for the treatment of haemophilia A. | 05-21-2009 |
20090029393 | METHOD FOR PREPARING ANTIBODIES SELECTIVE FOR ACTIVATING FC RECEPTORS - The present invention relates to a method for preparing an antibody selective for activating antibody Fc region receptors (FcRs) comprising an ITAM motif or motifs (immunoreceptor tyrosine-based activation motif), comprising the steps of obtaining monoclonal antibodies from a hybridoma, from a heterohybridoma or from any animal, plant or human cell line, replacing each of the His 310 and His 435 residues (Cabat numbering) of the Fc region of said antibody with a residue chosen from lysine, alanine, glycine, valine, leucine, isoleucine, proline, methionine, tryptophan, phenylalanine, serine or threonine, and then selecting the antibodies for which the binding to inhibitory FcRs comprising ITIM motifs (immunoreceptor tyrosine-based inhibition motif) is decreased by at least 30%, preferably by at least 50%, 70%, 80% or else by at least 90% relative to the same antibody having a natural Fc region. The present invention also relates to the use of an antibody derived from the method of the invention in the production of a medicament for use in particular in the treatment of cancer and of infectious pathologies. | 01-29-2009 |